Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
暂无分享,去创建一个
R. Bernards | A. Prahallad | Chong Sun | Sidong Huang | F. Nicolantonio | R. Salazar | D. Zecchin | R. Beijersbergen | A. Bardelli
[1] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[2] A. Boulares,et al. Transient Poly(ADP-ribosyl)ation of Nuclear Proteins and Role of Poly(ADP-ribose) Polymerase in the Early Stages of Apoptosis* , 1998, The Journal of Biological Chemistry.
[3] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[4] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[5] J. Lazo,et al. Identification of Epidermal Growth Factor Receptor as a Target of Cdc25A Protein Phosphatase* , 2002, The Journal of Biological Chemistry.
[6] M. Nikiforova,et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.
[7] Yuri E Nikiforov,et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.
[8] V. Trovisco,et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma , 2004, The Journal of pathology.
[9] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[10] René Bernards,et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors , 2006, Nature chemical biology.
[11] M. Kirschner,et al. Regulation of Cdc25C by ERK-MAP Kinases during the G2/M Transition , 2007, Cell.
[12] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[15] L. Pollak. Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.
[16] R. Labianca,et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[18] J. Barrett,et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Jan Koster,et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. , 2009, Cancer cell.
[20] F.A.M. Bordonaba,et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .
[21] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[23] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[24] Jo Lambert,et al. EGFR in melanoma: clinical significance and potential therapeutic target , 2011, Journal of cutaneous pathology.